- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT02930317
Evaluate Efficacy and Safety of Recombinant Factor VIII (rFVIII)Treatment of Severe or Moderately Severe Hemophilia A
11 ottobre 2016 aggiornato da: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
An Open-Label, Multicenter Evaluation of Safety, Pharmacokinetics, and Efficacy of rFVIII in the Prevention and Treatment of Bleeding Episodes in Chinese With Hemophilia A
Efficacy, Safety and Pharmacokinetics Study of a rFVIII in Chinese subjects with Hemophilia A.To assess efficacy and safety of rFVIII administered as treatment and as on-demand therapy in adult and adolescent (12-65 years) patients with severe or moderately severe Hemophilia A. To determine the pharmacokinetic (PK) parameters of rFVIII.
Panoramica dello studio
Stato
Sconosciuto
Condizioni
Intervento / Trattamento
Tipo di studio
Interventistico
Iscrizione (Anticipato)
60
Fase
- Fase 3
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Luoghi di studio
-
-
Anhui
-
Hefei, Anhui, Cina, 230001
- Reclutamento
- Anhui Provincial Hospital
-
Contatto:
- Zimin Sun, Doctor
-
-
Shanghai
-
Shanghai, Shanghai, Cina, 200025
- Non ancora reclutamento
- Ruijin Hospital Shanghai Jiaotong University School of Medicine
-
Contatto:
- Xuefeng Wang, Doctor
-
-
Shanxi
-
Taiyuan, Shanxi, Cina, 030001
- Non ancora reclutamento
- Second Hospital of Shanxi Medical University
-
Contatto:
- Linhua Yang, Doctor
-
-
Tianjin
-
Tianjin, Tianjin, Cina, 300020
- Reclutamento
- Blood Diseases Hospital, Chinese Academy of Medical Science (Institute of Hematology)
-
Contatto:
- Lei Zhang, Doctor
-
-
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
Da 12 anni a 65 anni (Bambino, Adulto, Adulto più anziano)
Accetta volontari sani
No
Sessi ammissibili allo studio
Tutto
Descrizione
Inclusion Criteria:
- Diagnosis of hemophilia A
- Age of 12 Years to 65 Years,Diagnosis of severe (defined as <1% FVIII:C documented in medical records) or moderately severe(defined as 1%-5% FVIII:C documented in medical records) hemophilia A .Subjects who(Age of 18 Years to 65 Years) have received or are currently receiving FVIII products (plasma-derived and/or recombinant FVIII) and have had >150 exposure days (EDs) with a FVIII product;The Callan (Age of 12 Years to 17) have received FVIII products and have had>50 EDs a FVIII product.
- Subjects without a past history of, or current no factor VIII inhibitor. For laboratory-based assessments, any Bethesda inhibitor titer Lower than the laboratory's normal range or <0.6 BU/mL (BU:Bethesda Units ).
- Liver and kidney function in accordance with the standard
- Subjects of childbearing potential should agree to use and utilize an adequate method of contraception throughout treatment and for at least 28 days after study is stopped
- Evidence of a personally or legally acceptable representative (legally acceptable representative is only applicable to Callan subjects) signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study
- The part one of subjects subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures; Subjects must be in a non bleeding state before the administration of rFVIII on Day 1; Subjects should not have received an infusion of any FVIII products for at least 3 days (at least 72 hours) before the administration of rFVIII on Day 1
Exclusion Criteria:
- Current FVIII inhibitor or history of FVIII inhibitor (>0.6 BU/mL )
- Diagnosed with any bleeding disorder in addition to hemophilia
- Documented Human Immunodeficiency Virus (HIV)
- Subjects anticipating elective surgery or other invasive procedure within 1 month following study entry
- Treatment with an immunomodulatory within 30 days or 5 half lives preceding Day 1, whichever is longer
- Subjects with known hypersensitivity to the active substance or to any of the excipients of rFVIII. Subjects with a known hypersensitivity to Chinese Human embryonic kidney cell proteins
- Subjects with severe anemia requiring blood transfusion
- Subjects with significant hepatic or renal impairment (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >5 x ULN, or total bilirubin >2 x ULN or serum creatinine >2 x ULN), prothrombin time >1.5 x ULN, platelet count <80,000 μL. History of sensitivity to heparin or heparin induced thrombocytopenia or others thrombocytopenia
- Patients with heart surgery history requires anticoagulation therapy; Subjects with severe heart disease, including myocardial infarction or heart failure Grade 3 or higher(NYHA Classification)
- Blood pressure unable to be controlled ideally(systolic pressure>150 mmHg,diastolic pressure>90 mmHg)
- Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Pharmacokinetic parameters
Pharmacokinetic parameters of rFVIII measured in subset of 10 participants, consisting of:18 Years to 65 Years.
In Part 1 of the study, subjects received a single intravenous infusion of 50 IU/kg rFVIII preceded by a 72 hours washout period.
|
|
|
Sperimentale: On-demand treatment
On-demand treatment with rFVIII for 6 months age 12 Years to 65 Years.
In Parts 2 of the study, subjects received repeat injections of rFVIII either as an on-demand or prophylaxis regimen at a dose and frequency determined by their study doctor.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Recovery rate = (change actual value of rFVIII activity before and after infusion )/(change expected value of rFVIII activity before and after infusion)*100%
Lasso di tempo: At 15 and 60 minutes after the first infusion
|
At 15 and 60 minutes after the first infusion
|
|
|
Investigator Hemostatic Efficacy Assessment 6 Hours Post Infusion
Lasso di tempo: 6 hours post infusion
|
The Investigator Hemostatic Efficacy Assessment was based on a 4-point rating scale (Excellent = 1: definite pain relief or improvement in signs of bleeding, with no additional infusion, Good = 2: definite pain relief or improvement in signs of bleeding, Moderate = 3: probable or slight improvement, No Response = 4: no improvement at all between infusions).
|
6 hours post infusion
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
The proportion of subjects who achieved the expected effect after the first infusion of the rFVIII
Lasso di tempo: At 15 minutes after the first infusion
|
At 15 minutes after the first infusion
|
|
change actual value of rFVIII activity before and after infusion levels
Lasso di tempo: At 15 and 60 minutes after the first infusion
|
At 15 and 60 minutes after the first infusion
|
|
FVIII Maximum Plasma Concentration
Lasso di tempo: Time Frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 6, 9, 24,36,and 48 hours post-dose
|
Time Frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 6, 9, 24,36,and 48 hours post-dose
|
|
Time to Reach Maximum Observed Plasma Concentration
Lasso di tempo: Time Frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 6, 9, 24,36,and 48 hours post-dose
|
Time Frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 6, 9, 24,36,and 48 hours post-dose
|
|
Area Under the Plasma Concentration Versus Time Curve From 0 to 48 Hours
Lasso di tempo: Time Frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 6, 9, 24,36,and 48 hours post-dose
|
Time Frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 6, 9, 24,36,and 48 hours post-dose
|
|
Terminal Elimination Half-Life (t1/2)
Lasso di tempo: Time Frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 6, 9, 24,36,and 48 hours post-dose
|
Time Frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 6, 9, 24,36,and 48 hours post-dose
|
|
Time to Reach Maximum Observed Plasma Concentration (Tmax)
Lasso di tempo: Time Frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 6, 9, 24,36,and 48 hours post-dose
|
Time Frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 6, 9, 24,36,and 48 hours post-dose
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)
Lasso di tempo: Up to 28 days after last dose
|
An AE was any untoward medical occurrence in a participant who received study drug.
An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Treatment-emergent are events between first dose of study drug and up to 28 days after last dose after last dose that were absent before treatment or that worsened relative to pre-treatment state.
AEs included both SAEs and non-SAEs.
|
Up to 28 days after last dose
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio
1 agosto 2016
Completamento primario (Anticipato)
1 ottobre 2017
Completamento dello studio (Anticipato)
1 dicembre 2017
Date di iscrizione allo studio
Primo inviato
9 settembre 2016
Primo inviato che soddisfa i criteri di controllo qualità
11 ottobre 2016
Primo Inserito (Stima)
12 ottobre 2016
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
12 ottobre 2016
Ultimo aggiornamento inviato che soddisfa i criteri QC
11 ottobre 2016
Ultimo verificato
1 ottobre 2016
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- CTTQ-NXBYZ
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Indeciso
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .